Sanavia Oncology
Sanavia Oncology develops novel immunotherapies to help patients facing drug-resistant cancer. Using a proprietary platform that combines artificial intelligence with modern immunology, the company identifies cancer-specific epitopes and generates targeted antibodies, leveraging technologies such as high throughput sequencing and 3D protein modeling. The team includes researchers from Memorial Sloan-Kettering Cancer Center, Rockefeller University, Weill Cornell Medicine, and Columbia University. Based in New York, Sanavia focuses on validating targets and delivering effective treatments for oncology patients.
Sanavia Oncology
Sanavia Oncology develops novel immunotherapies to help patients facing drug-resistant cancer. Using a proprietary platform that combines artificial intelligence with modern immunology, the company identifies cancer-specific epitopes and generates targeted antibodies, leveraging technologies such as high throughput sequencing and 3D protein modeling. The team includes researchers from Memorial Sloan-Kettering Cancer Center, Rockefeller University, Weill Cornell Medicine, and Columbia University. Based in New York, Sanavia focuses on validating targets and delivering effective treatments for oncology patients.